Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

346

Participants

Timeline

Start Date

August 27, 2020

Primary Completion Date

September 10, 2024

Study Completion Date

September 30, 2029

Conditions
Biochemically Recurrent Prostate CarcinomaMetastatic Prostate CarcinomaStage IIIB Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8
Interventions
OTHER

Interview

Attend Interview

OTHER

Internet Based Intervention

Use web-based genetic education tool online

OTHER

Survey Administration

Ancillary Studies

OTHER

Genetic Counseling

Receive in-person, telehealth, or over-the-phone genetic counseling

GENETIC

Genetic Testing

Undergo genetic testing

OTHER

Survey Administration

Ancillary Studies

OTHER

Genetic Counseling

Receive in-person, telehealth, or over-the-phone genetic counseling

OTHER

Internet-Based Intervention

Use web-based genetic education tool online

GENETIC

Genetic Testing

Undergo genetic testing

OTHER

Survey Administration

Ancillary Studies

Trial Locations (5)

10010

VA New York Harbor Health System- Manhattan Campus, New York

10016

New York University- Langone Health, New York

13210

Associated Medical Professions of New York, Syracuse

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

98109

University of Washington/ SCCA, Seattle

All Listed Sponsors
collaborator

Prostate Cancer Foundation

OTHER

lead

Thomas Jefferson University

OTHER